Immunitybio Book Value Per Share from 2010 to 2024

IBRX Stock

USD 5.04 0.06 1.18%

Immunitybio Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Immunitybio according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(1.15)

Current Value

(1.09)

Quarterly Volatility

2.72186526

Credit Downgrade

Yuan Drop

Covid

Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.8 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many indicators such as Price To Sales Ratio of 6.7 K, Dividend Yield of 0.0 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.

Check out the analysis of Immunitybio Correlation against competitors.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Immunitybio over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Immunitybio's Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (1.07) X

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Immunitybio Book Value Per Share Regression Statistics

	Arithmetic Mean	(0.35)
	Coefficient Of Variation	(783.24)
	Mean Deviation	2.10
	Median	(0.63)
	Standard Deviation	2.72
	Sample Variance	7.41
	Range	8.6095
	R-Value	0.26
	Mean Square Error	7.43
	R-Squared	0.07
	Significance	0.35
	Slope	0.16
	Total Sum of Squares	103.72

Immunitybio Book Value Per Share History

	2024	-1.09
	2023	-1.15
	2022	-1.12
	2021	-0.63
	2020	-0.31
	2019	0.31
	2018	1.85

Other Fundumenentals of Immunitybio

Tangible Book Value Per Share

Immunitybio Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Capital Stock	Net Working Capital	Deferred Long Term Liab	Short Long Term Debt
Total Assets		-0.38	-0.82	0.61	-0.75	0.64	0.23	0.68	0.95	0.45	0.57	0.7	-0.31	0.73	0.65	-0.64	0.53	0.41	-0.7	0.55	-0.03	-0.33	0.56
Total Stockholder Equity	-0.38		0.28	-0.91	0.86	-0.64	0.03	-0.92	-0.24	-0.44	-0.64	-0.87	0.7	-0.83	-0.85	0.91	-0.67	-0.28	0.87	-0.75	-0.06	0.68	-0.82
Current Deferred Revenue	-0.82	0.28		-0.53	0.72	-0.6	-0.45	-0.57	-0.69	-0.32	-0.57	-0.65	0.52	-0.58	-0.56	0.58	-0.32	-0.27	0.51	-0.36	0.02	0.32	-0.41
Net Debt	0.61	-0.91	-0.53		-0.93	0.86	0.04	0.93	0.44	0.68	0.66	0.89	-0.62	0.91	0.86	-0.95	0.51	0.53	-0.94	0.61	-0.19	-0.53	0.76
Retained Earnings	-0.75	0.86	0.72	-0.93		-0.78	-0.17	-0.97	-0.6	-0.47	-0.75	-0.98	0.73	-0.91	-0.91	0.96	-0.68	-0.35	0.91	-0.75	-0.05	0.67	-0.82
Accounts Payable	0.64	-0.64	-0.6	0.86	-0.78		0.05	0.71	0.45	0.81	0.56	0.69	-0.5	0.85	0.68	-0.83	0.21	0.52	-0.73	0.32	-0.54	-0.15	0.59
Net Receivables	0.23	0.03	-0.45	0.04	-0.17	0.05		0.09	0.16	-0.05	0.01	0.12	-0.26	0.07	0.1	-0.05	0.11	-0.08	-0.04	0.12	0.09	-0.1	0.1
Total Liab	0.68	-0.92	-0.57	0.93	-0.97	0.71	0.09		0.56	0.46	0.75	0.98	-0.68	0.88	0.94	-0.95	0.72	0.36	-0.95	0.79	0.1	-0.75	0.85
Total Current Assets	0.95	-0.24	-0.69	0.44	-0.6	0.45	0.16	0.56		0.33	0.4	0.58	-0.09	0.58	0.5	-0.46	0.49	0.43	-0.59	0.47	0.09	-0.29	0.4
Short Term Debt	0.45	-0.44	-0.32	0.68	-0.47	0.81	-0.05	0.46	0.33		0.36	0.35	-0.21	0.6	0.43	-0.57	-0.09	0.8	-0.65	0.01	-0.79	0.13	0.32
Intangible Assets	0.57	-0.64	-0.57	0.66	-0.75	0.56	0.01	0.75	0.4	0.36		0.72	-0.76	0.62	0.81	-0.82	0.54	0.02	-0.71	0.66	-0.05	-0.62	0.84
Common Stock	0.7	-0.87	-0.65	0.89	-0.98	0.69	0.12	0.98	0.58	0.35	0.72		-0.7	0.87	0.9	-0.93	0.73	0.28	-0.88	0.79	0.2	-0.77	0.81
Short Term Investments	-0.31	0.7	0.52	-0.62	0.73	-0.5	-0.26	-0.68	-0.09	-0.21	-0.76	-0.7		-0.61	-0.72	0.76	-0.51	0.09	0.56	-0.61	-0.04	0.58	-0.74
Capital Surpluse	0.73	-0.83	-0.58	0.91	-0.91	0.85	0.07	0.88	0.58	0.6	0.62	0.87	-0.61		0.79	-0.92	0.65	0.41	-0.86	0.7	-0.14	-0.38	0.79
Property Plant Equipment	0.65	-0.85	-0.56	0.86	-0.91	0.68	0.1	0.94	0.5	0.43	0.81	0.9	-0.72	0.79		-0.91	0.7	0.25	-0.91	0.79	0.07	-0.75	0.89
Net Tangible Assets	-0.64	0.91	0.58	-0.95	0.96	-0.83	-0.05	-0.95	-0.46	-0.57	-0.82	-0.93	0.76	-0.92	-0.91		-0.6	-0.32	0.91	-0.71	0.11	0.62	-0.87
Long Term Debt	0.53	-0.67	-0.32	0.51	-0.68	0.21	0.11	0.72	0.49	-0.09	0.54	0.73	-0.51	0.65	0.7	-0.6		-0.14	-0.62	0.98	0.56	-0.68	0.8
Net Invested Capital	0.41	-0.28	-0.27	0.53	-0.35	0.52	-0.08	0.36	0.43	0.8	0.02	0.28	0.09	0.41	0.25	-0.32	-0.14		-0.56	-0.13	-0.46	0.09	-0.03
Long Term Investments	-0.7	0.87	0.51	-0.94	0.91	-0.73	-0.04	-0.95	-0.59	-0.65	-0.71	-0.88	0.56	-0.86	-0.91	0.91	-0.62	-0.56		-0.7	0.08	0.61	-0.79
Capital Stock	0.55	-0.75	-0.36	0.61	-0.75	0.32	0.12	0.79	0.47	0.01	0.66	0.79	-0.61	0.7	0.79	-0.71	0.98	-0.13	-0.7		0.46	-0.74	0.9
Net Working Capital	-0.03	-0.06	0.02	-0.19	-0.05	-0.54	0.09	0.1	0.09	-0.79	-0.05	0.2	-0.04	-0.14	0.07	0.11	0.56	-0.46	0.08	0.46		-0.59	0.07
Deferred Long Term Liab	-0.33	0.68	0.32	-0.53	0.67	-0.15	-0.1	-0.75	-0.29	0.13	-0.62	-0.77	0.58	-0.38	-0.75	0.62	-0.68	0.09	0.61	-0.74	-0.59		-0.65
Short Long Term Debt	0.56	-0.82	-0.41	0.76	-0.82	0.59	0.1	0.85	0.4	0.32	0.84	0.81	-0.74	0.79	0.89	-0.87	0.8	-0.03	-0.79	0.9	0.07	-0.65

Click cells to compare fundamentals

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	(1.15)	(1.09)
Tangible Book Value Per Share	(1.19)	(1.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC